Evoke Pharma, Inc.

149 articles with Evoke Pharma, Inc.

• Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

  3/21/2023

  Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2022, and recent corporate developments.

• Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023

  3/15/2023

  Evoke Pharma, Inc. today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes.

• Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session

  2/21/2023

  Evoke Pharma, Inc. today announced that its abstract entitled “Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide” has been selected for the plenary lecture presentation at the upcoming Digestive Disease Week (DDW) 2023.

• Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against GimotiStipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed

  1/30/2023

  Evoke Pharma, Inc. today announced that a joint stipulation of dismissal has been filed in the GIMOTI ® patent infringement case (Civil Action No. 1:22-cv-02019) in the United States District Court for the District of New Jersey.

• Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

  1/18/2023

  Evoke Pharma, Inc. today announced that its abstract entitled “Real-World Healthcare Resource Utilization of Patients Treated with Metoclopramide Nasal for Diabetic Gastroparesis (DGP)” will be presented at the Academy of Managed Care Pharmacy (AMCP) annual meeting.

• USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis

  12/7/2022

  Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate and Severe Gastroparesis.”

• Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

  11/30/2022

  Evoke Pharma, Inc. announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI.

• Evoke Pharma Reports Record Third Quarter 2022 Financial Results

  11/9/2022

  Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases, announced its financial results for the third quarter ended September 30, 2022 and recent corporate developments.

• Evoke Pharma to Report Third Quarter Results on November 9, 2022

  11/2/2022

  Evoke Pharma, Inc. today announced that the Company is scheduled to release its third quarter on Wednesday, November 9, 2022, after the market closes.

• Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting

  10/20/2022

  Evoke Pharma, Inc.  today announced that the Company will participate in the 2022 American College of Gastroenterology Annual Scientific Meeting taking place from October 21 – 26, 2022 in Charlotte, North Carolina.

• Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI

  9/20/2022

  Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 16/469,092 for GIMOTI. 

• GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award

  9/14/2022

  Evoke Pharma, Inc. announced that its flagship product, GIMOTI has been nominated for Healio’s Annual Disruptive Innovators Awards under the Healio Industry Breakthrough Award category.

• Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Evoke Pharma, Inc. (NASDAQ: EVOK), today announced that the Company’s President and CEO, David A. Gonyer, R.Ph., and Chief Business Officer, Matt D’Onofrio, MBA, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022, at the Lotte New York Palace Hotel in NYC.

• Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth SolutionPatients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealth

  8/16/2022

  Evoke Pharma, Inc. and EVERSANA™, today announced that Evoke, through its wide-scale commercialization partnership with EVERSANA, is launching a telehealth solution for patients.

• Evoke Pharma Reports Second Quarter 2022 Financial Results

  8/10/2022

  Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases, announced its financial results for the second quarter ended June 30, 2022, and recent corporate developments.

• Evoke Pharma to Report Second Quarter Results on August 10, 2022

  8/3/2022

  Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its second quarter on Wednesday, August 10, 2022, after the market closes.

• Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)

  8/1/2022

  Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced their ongoing collaboration with the International Foundation for Gastrointestinal Disorders (IFFGD) for Gastroparesis Awareness Month celebrated in August each year.

• Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

  7/6/2022

  Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Canadian Intellectual Property Office granted the Company a key patent for its previously submitted application (CA 2984736) “Nasal Formulations of Metoclopramide.”

• Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

  6/15/2022

  Evoke Pharma, Inc. today announced that the Florida Medicaid Pharmaceutical & Therapeutics Committee has approved adding GIMOTI, the Company’s novel treatment solution meant to treat symptoms associated with acute and recurrent diabetic gastroparesis.

• Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

  6/8/2022

  Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it received written notice from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price.